Publicação

Harnessing complex metabolic signatures to predict drug efficacy in ovarian cancer

Detalhes bibliográficos
Resumo:	"Ovarian carcinoma (OvC) is the most lethal gynecologic malignancy. Unfortunately, most cases are diagnosed at the later stages of the disease, impacting patient outcomes, resulting in a 5-year survival rate of less than 40%. The standard-of-care (SOC) treatment consists of cytoreduction surgery for tumor debulking and adjuvant chemotherapy, comprising a combination of platinum (cisplatin or carboplatin) with taxane (paclitaxel or docetaxel) agents.(...)"
Autores principais:	Mendes, Ana Rita Soares
Assunto:	precision medicine ovarian cancer
Ano:	2022
País:	Portugal
Tipo de documento:	tese de doutoramento
Tipo de acesso:	acesso aberto
Instituição associada:	Universidade Nova de Lisboa
Idioma:	inglês
Origem:	Repositório Institucional da UNL

Registos relacionados

Recycling the purpose of old drugs to treat ovarian cancer
por: Nunes, M
Publicado em: (2020)

Quality of life in ovarian cancer survivors
por: Gonçalves, Vânia
Publicado em: (2015)

Combining paclitaxel with repurposing drugs improve ovarian cancer management
por: Nunes, Mariana
Publicado em: (2022)

Exploring Metabolic Signatures of Ex Vivo Tumor Tissue Cultures for Prediction of Chemosensitivity in Ovarian Cancer
por: Mendes, Rita
Publicado em: (2022)

Ovarian cancer zebrafish avatar for personalized therapy
por: Amorim, Filipa Alexandra Mesquita
Publicado em: (2022)

Deep learning for drug response prediction in cancer
por: Baptista, Delora
Publicado em: (2021)

Importance of xeroderma pigmentosum group D polymorphisms in susceptibility to ovarian cancer
por: Costa, Sandra Maria Araújo da
Publicado em: (2007)

Glutathione in Ovarian Cancer
por: Nunes, Sofia C.
Publicado em: (2018)

Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome
por: Vicente, Rodrigo
Publicado em: (2022)

Chemotherapy-free treatment of recurrent advanced ovarian cancer
por: Marques, Cristiana
Publicado em: (2023)

The influence of tumor microenvironment immune in ovarian cancer ascites
por: Nunes, Diana
Publicado em: (2022)

Ultrasensitive detection of ovarian cancer marker using immunoliposomes and gold nanoelectrodes
por: Viswanathan, Subramanian
Publicado em: (2012)

Tumor-targeting polycaprolactone nanoparticles with codelivery of paclitaxel and IR780 for combinational therapy of drug-resistant ovarian cancer
por: Pan, Q.
Publicado em: (2020)

Predictive biomarkers and patient outcome in platinum-resistant (PLD-treated) ovarian cancer
por: Sousa, IJD
Publicado em: (2020)

Update on imaging of ovarian cancer
por: Forstner, Rosemarie
Publicado em: (2016)

Molecular imprinted nanoelectrodes for ultra sensitive detection of ovarian cancer marker
por: Viswanathan, Subramanian
Publicado em: (2012)

Epithelial-mesenchymal interconversions in ovarian cancer: The levels and functions of E-cadherin in intraabdominal dissemination
por: Roque, Ricardo
Publicado em: (2020)

Ivermectin decreases the expression of ALDH1 in ovarian cancer cell lines in combination with chemotherapy
por: Santos, Cláudia
Publicado em: (2025)

DNA content evaluation for epithelial ovarian cancer identification
por: Tomé, António
Publicado em: (2018)

Immune tumor microenvironment in ovarian cancer ascites
por: Almeida-Nunes, Diana Luísa
Publicado em: (2022)

Phenotypic evaluation of the ovarian tumor cells presents in malignant ascites
por: Ferreira, Sílvia
Publicado em: (2022)

Validation of next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer
por: Theisen, Patrícia
Publicado em: (2015)

Early detection of breast, cervical, ovarian and endometrial cancers in low resource countries: an integrated approach
por: Shetty, Mahesh K.
Publicado em: (2011)

Is There a Role for Risk-Reducing Bilateral Breast Surgery in BRCA1/2 Ovarian Cancer Survivors? An Observational Study
por: Oliveira, Daniela
Publicado em: (2023)

Characterization of extracellular vesicles from ascitic fluid in ovarian cancer patients
por: Rodrigues, Leandra José Silva
Publicado em: (2022)

Relapsed Ovarian Cancer patients with ascites and/or pleural effusion still benefit from treatment: A real-life study
por: Rebordão-Pires, Mariana
Publicado em: (2023)

Malignant ascites microenvironment kinetics during ovarian cancer metastization: comprehension of therapeutic resistances
por: Nunes, Diana Luísa de Almeida
Publicado em: (2025)

Specific antiproliferative properties of proteinaceous toxin secretions from the marine annelid Eulalia sp. onto ovarian cancer cells
por: Rodrigo, Ana P.
Publicado em: (2021)

Specific Antiproliferative Properties of Proteinaceous Toxin Secretions from the Marine Annelid Eulalia sp. onto Ovarian Cancer Cells
por: Rodrigo, Ana P.
Publicado em: (2021)

Evaluation of the role of LRP1B in the response of human ovarian cancer cells to liposomal doxorubicin
por: Saraiva, Inês de Andrade Matos Gonçalves
Publicado em: (2018)

Peripheral Blood Serum NMR Metabolomics Is a Powerful Tool to Discriminate Benign and Malignant Ovarian Tumors
por: Nunes, Sofia C.
Publicado em: (2023)

Ovarian Torsion Mimicking a Malignant Ovarian Tumour
por: Sousa,Filipa Alves e
Publicado em: (2022)

Inhibition of CXCR2 Plays a Pivotal Role in Re-Sensitizing Ovarian Cancer to Cisplatin Treatment
por: Henriques, TB
Publicado em: (2021)

Precision biomaterials in cancer theranostics and modelling
por: Caballero, David
Publicado em: (2022)

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline
por: Sessa, C.
Publicado em: (2023)

Cysteine Boosts Fitness Under Hypoxia-Mimicked Conditions in Ovarian Cancer by Metabolic Reprogramming
por: Nunes, Sofia C.
Publicado em: (2021)

Protein glycosylation of extracellular vesicles from ovarian carcinoma cells
por: Gomes, Joana Raquel Afonso
Publicado em: (2015)

Ovarian dysgerminoma
por: Amante, Sofia
Publicado em: (2023)

Performance of ultrasound models in diagnosis of Ovarian Cancer: Experience of a Portuguese tertiary center
por: Rodrigues,Ângela
Publicado em: (2020)

BRCA1 and BRCA2 variants identified in patients with a personal/familial history of hereditary breast/ovarian cancers and other hereditary cancer syndromes: challenges related with variants of uncertain significance
por: Rodrigues, Pedro
Publicado em: (2021)